

News Releases

All Years

Search

Go

[Advanced Search](#)

JUL 16, 2026

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to \$500.0 Million

JUN 15, 2026

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

MAY 14, 2026

Inhibrx Reports First Quarter 2026 Financial Results

MAY 11, 2026

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

MAY 8, 2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

APR 21, 2026

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

APR 20, 2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update

Inhibrx to Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

MAR 19, 2026

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

MAR 2, 2026

Inhibrx Announces Participation in Upcoming Scientific Conference

DEC 16, 2025

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Show per
page

«	1	2	3	4	5	6	7	8	»
---	---	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	---



<https://inhibrxbiosciences.investorroom.com/news-releases?l=10>